November 04, 2024
Developing treatments for people with mental health conditions
October 14, 2024
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare
October 09, 2024
Boehringer Ingelheim collaborates with Circle Pharma
October 08, 2024
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
September 27, 2024
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
September 25, 2024
Boehringer Ingelheim expands cancer research at its Vienna site
September 16, 2024
Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
September 09, 2024
Zongertinib shows encouraging efficacy and tolerability profile in lung cancer patients
September 05, 2024
Geographic Atrophy treatment to move to Phase II
September 03, 2024
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
August 30, 2024
Boehringer Ingelheim announces appointments Board of Managing Directors
August 27, 2024
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC
Media Contacts
Head of Global Media Relations
E-Mail:
harro.ten_wolde@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-181352
Senior Media Relations Manager
E-Mail:
tereza.urbankova@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-184817
Head of Human Pharma Communications
E-Mail:
anthonia.aboyeji@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-172370
Head of Animal Health Communications
E-Mail:
Heidi.DeWit-Sommerfeld@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-171799